Source comparison
Pharmacokinetic Profiles — Pulsatile vs Sustained Release
The half-life difference between CJC-1295 and CJC-1295 with DAC isn't a matter of convenience. It determines which biological questions each peptide can address. Standard CJC-1295 reaches peak plasma concentration within 20–30 minutes of subcutaneous administr
This comparison does not assign a generated winner or score.
- The half-life difference between CJC-1295 and CJC-1295 with DAC isn't a matter of convenience. It determines which biological questions each peptide can address. Standard CJC-1295 reaches peak plasma concentration within 20–30 minutes of subcutaneous administration, stimulates a GH pulse that peaks 30–60 minutes later, and clears almost completely within 4 hours. This mirrors the kinetics of endogenous GHRH, making it suitable for protocols examining acute response, dose-response curves, receptor sensitivity, or circadian alignment.
- CJC-1295 with DAC produces measurable plasma levels within 1–2 hours, reaches steady-state concentration by day 3, and maintains that level for 5–7 days post-injection. The albumin-binding mechanism means the peptide is never fully 'cleared' in the traditional sense. It's gradually released from its carrier protein and metabolised over the course of a week. This creates tonic GH elevation without the peaks and troughs characteristic of pulsatile secretion.
- The clinical implication: if your research question involves examining how the GH axis responds to intermittent stimulation, or how feedback inhibition modulates secretory amplitude, CJC-1295 with DAC introduces a fundamentally different stimulus than the physiological one you're trying to model. Conversely, if you're studying the effects of sustained GH elevation on metabolic endpoints. Protein synthesis rates, lipolysis, glucose handling. The DAC variant provides a stable baseline increase that simplifies interpretation.
- One insight most peptide suppliers won't mention: the DAC modification also changes injection frequency requirements in ways that affect experimental design. Standard CJC-1295 typically requires dosing 1–3 times daily to maintain elevated GH across multiple pulses. CJC-1295 with DAC requires only one injection every 5–7 days. For long-duration studies, that difference in handling frequency can introduce variability. More frequent injections mean more opportunities for administration errors, but also tighter control over when the peptide is active.